Actavis Inc (ACT) 254.20 $ACT
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension
PR Newswire - Wed Dec 24, 12:15PM CST
Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
ACT: 254.20 (-1.68)
FDA clears Adamas Alzheimer's drug
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 7:52AM CST
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
PR Newswire - Wed Dec 24, 7:00AM CST
Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 5:05PM CST
Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application for Imbruvica for WM indication by Apr 17, 2015.
AGN: 210.12 (+0.95), JNJ: 104.59 (+0.31), ACT: 254.20 (-1.68), PCYC: 121.84 (+1.15)
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Actavis hires Jonathon Kellerman as EVP
M2 - Tue Dec 23, 5:27AM CST
Pharmaceutical company Actavis (NYSE:ACT) disclosed on Monday the appointment of Jonathon Kellerman as executive vice president and global chief compliance officer.
ACT: 254.20 (-1.68)
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive
at Investor's Business Daily - Mon Dec 22, 5:23PM CST
Investors turned a bit skittish on medical stocks Monday, as Gilead Sciences (GILD) plunged after Express Scripts (ESRX) announced it would support the hepatitis C drug from AbbVie (ABBV), rather than Gilead's Sovaldi. But two IBD Stock Spotlight...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:51PM CST
Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer to EU approval.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer
PR Newswire - Mon Dec 22, 8:24AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Jonathon Kellerman has joined the Company as Executive Vice President, Global Chief Compliance Officer. Mr. Kellerman is a member of the Actavis Executive Leadership Team (ELT) and will report directly to Brent Saunders, CEO and President. He will also be an integral member of the Actavis and Allergan pre-integration planning team as well as integration activities following the close.
ACT: 254.20 (-1.68)
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Dec 22, 8:00AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
ACT: 254.20 (-1.68), JPM: 62.48 (unch)
Top Pharmaceutical Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 20, 8:05AM CST
Source: Flickr user stockmonkeys.com. It has been tough lately for big pharmaceutical stocks to overcome the headwinds tied to patent expiration on some of the world's best-selling medicines. As a result, pharmaceutical stocks haven't been as...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), JAZZ: 165.33 (+1.83)
XYDALBA(TM) (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults
PR Newswire - Fri Dec 19, 3:15PM CST
Actavis plc (NYSE: ACT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted Actavis' subsidiary Durata Therapeutics International, B.V., a positive opinion for XYDALBA (dalbavancin), for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
PR Newswire - Fri Dec 19, 8:00AM CST
Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston, MA.
ACT: 254.20 (-1.68)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Baidu, Alibaba Among Top World Stocks Building Bases
at Investor's Business Daily - Thu Dec 18, 5:09PM CST
This is the time when investors should be building watch lists, and the Top World Stocks list offers a range of possible candidates. Three stocks on the list (to the right), Avago Technologies (AVGO), Cimpress (CMPR) and Radware (RDWR), are clearly...
MNK: 97.84 (-0.29), RDWR: 22.18 (+0.24), ACT: 254.20 (-1.68), BIDU: 230.98 (-2.18), HDB: 50.86 (-0.06), CMPR: 75.76 (+0.05), NXPI: 76.75 (+0.48), AVGO: 100.72 (-0.06), BABA: 105.95 (+0.43)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 38.86 (+0.53), ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), CYCC: 0.69 (+0.01), SCMP: 13.75 (+0.44)
Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension
PR Newswire - Wed Dec 24, 12:15PM CST
Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
ACT: 254.20 (-1.68)
FDA clears Adamas Alzheimer's drug
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 7:52AM CST
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
PR Newswire - Wed Dec 24, 7:00AM CST
Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 5:05PM CST
Pharmacyclics, Inc. (PCYC) announced that the FDA is expected to render a final opinion on the supplemental New Drug Application for Imbruvica for WM indication by Apr 17, 2015.
AGN: 210.12 (+0.95), JNJ: 104.59 (+0.31), ACT: 254.20 (-1.68), PCYC: 121.84 (+1.15)
Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)
Actavis hires Jonathon Kellerman as EVP
M2 - Tue Dec 23, 5:27AM CST
Pharmaceutical company Actavis (NYSE:ACT) disclosed on Monday the appointment of Jonathon Kellerman as executive vice president and global chief compliance officer.
ACT: 254.20 (-1.68)
Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive
at Investor's Business Daily - Mon Dec 22, 5:23PM CST
Investors turned a bit skittish on medical stocks Monday, as Gilead Sciences (GILD) plunged after Express Scripts (ESRX) announced it would support the hepatitis C drug from AbbVie (ABBV), rather than Gilead's Sovaldi. But two IBD Stock Spotlight...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86)
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:51PM CST
Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer to EU approval.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)
Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer
PR Newswire - Mon Dec 22, 8:24AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Jonathon Kellerman has joined the Company as Executive Vice President, Global Chief Compliance Officer. Mr. Kellerman is a member of the Actavis Executive Leadership Team (ELT) and will report directly to Brent Saunders, CEO and President. He will also be an integral member of the Actavis and Allergan pre-integration planning team as well as integration activities following the close.
ACT: 254.20 (-1.68)
Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Dec 22, 8:00AM CST
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
ACT: 254.20 (-1.68), JPM: 62.48 (unch)
Top Pharmaceutical Stocks to Buy for 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Dec 20, 8:05AM CST
Source: Flickr user stockmonkeys.com. It has been tough lately for big pharmaceutical stocks to overcome the headwinds tied to patent expiration on some of the world's best-selling medicines. As a result, pharmaceutical stocks haven't been as...
VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), JAZZ: 165.33 (+1.83)
XYDALBA(TM) (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults
PR Newswire - Fri Dec 19, 3:15PM CST
Actavis plc (NYSE: ACT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted Actavis' subsidiary Durata Therapeutics International, B.V., a positive opinion for XYDALBA (dalbavancin), for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
DRTX: 24.16 (+0.41), ACT: 254.20 (-1.68)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
PR Newswire - Fri Dec 19, 8:00AM CST
Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, today announced that Brent Saunders, CEO and President of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston, MA.
ACT: 254.20 (-1.68)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Baidu, Alibaba Among Top World Stocks Building Bases
at Investor's Business Daily - Thu Dec 18, 5:09PM CST
This is the time when investors should be building watch lists, and the Top World Stocks list offers a range of possible candidates. Three stocks on the list (to the right), Avago Technologies (AVGO), Cimpress (CMPR) and Radware (RDWR), are clearly...
MNK: 97.84 (-0.29), RDWR: 22.18 (+0.24), ACT: 254.20 (-1.68), BIDU: 230.98 (-2.18), HDB: 50.86 (-0.06), CMPR: 75.76 (+0.05), NXPI: 76.75 (+0.48), AVGO: 100.72 (-0.06), BABA: 105.95 (+0.43)
Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), EBS: 27.64 (+1.28), SCMP: 13.75 (+0.44)
Tetraphase Jumps As 'Superbug' Drug Scores In Trial
at Investor's Business Daily - Thu Dec 18, 10:54AM CST
Biotech Tetraphase Pharmaceuticals (TTPH) jumped 16% to a new high Thursday and got a volley of price target increases after it reported positive trial results for its antibiotic late Wednesday. The trial found Tetraphase's eravacycline to be...
TTPH: 38.86 (+0.53), ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)
Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 254.20 (-1.68), VRX: 140.33 (-0.22), CYCC: 0.69 (+0.01), SCMP: 13.75 (+0.44)
